Last reviewed · How we verify

NCT04099043: CASPA

Cascade CGM 15-day Performance Assessment

Completed NA Last updated 6 April 2020
What this trial tests

NA trial testing Cascade Continuous Glucose Monitoring System in Continuous Glucose Monitoring in 10 participants. Completed in 13 October 2019.

Timeline
28 September 2019
Primary endpoint
13 October 2019
13 October 2019

Quick facts

Lead sponsorWaveForm Technologies Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment10
Start date28 September 2019
Primary completion13 October 2019
Estimated completion13 October 2019
Sites1 location across Slovenia

Drugs / interventions tested

Conditions studied

Sponsor

WaveForm Technologies Inc.

Who can join

18 and older, any sex, with Continuous Glucose Monitoring. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To validate the feasibility of a 15-day wear period of the Cascade CGM system

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A Prospective Multicenter Clinical Performance Evaluation of the C-CGM System.
    Rebec M, Cai K, Dutt-Ballerstadt R, Anderson E. · · 2022 · cited 10× · PMID 33084416 · DOI 10.1177/1932296820964574

Verify or expand the search:

Other recruiting trials for Continuous Glucose Monitoring

Currently open trials in the same condition.

Other WaveForm Technologies Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04099043.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing